Reuters reports FDA leaders pushed staff to shorten the obesity pill review

FDA leadership pressed internal reviewers to shorten the evaluation timeline for Eli Lilly's experimental obesity pill orforglipron, according to internal documents reviewed by Reuters and published December 12, 2025.^[1] The push came after Lilly sought a faster decision under the agency's new National Priority Voucher program, which is meant to fast-track reviews of drugs seen as addressing critical public health needs.^[1]

The FDA Commissioner's Office asked reviewers to cut the time spent checking whether an application has enough material to review from 60 days to just one week, documents show.^[1] After pushback from staff, the office said it might instead cut that filing check to two or three weeks depending on the drug's complexity, though Reuters could not confirm whether any change would actually take effect.^[1] FDA reviewers had originally set a 180-day review period with a target decision date of May 20, 2026.^[1] If a shorter filing review is adopted, the agency could issue a decision on orforglipron as early as March 28, 2026.^[1]

Lilly first asked for a 60-day review with a January 2026 decision, then argued for a March 30, 2026 verdict, saying its application was complete and that technical and labeling reviews could run alongside the filing check.^[1] The company also referenced its recent pricing deal with the Trump administration in communications with FDA staff, though it acknowledged the agency's independent authority to decide.^[1] Lilly received its priority voucher in November 2025 as part of that deal, which lowers prices for its weight-loss drugs for government programs and cash-paying patients; CEO David Ricks said at the time he expected a March decision.^[1]

In a late-stage trial, orforglipron helped patients lose 12.4% of their body weight.^[1] In a separate trial, Novo Nordisk's oral semaglutide pill led to 16.6% weight loss.^[1] Novo Nordisk is expected to launch its own weight-loss pill in December 2025 or January 2026.^[1] Analysts estimate the obesity drug market could be worth $150 billion a year by the early 2030s.^[1]

An FDA source who was not authorized to speak publicly told Reuters that the speed of these reviews is concerning. "Americans will be at risk with this approach," the source said. "The mandate for speed, instead of quality, creates a real possibility that a safety or efficacy issue will not get the meaningful attention it deserves, or that it will be missed entirely."^[1] A Department of Health and Human Services spokesperson said the voucher program is meant to address health priorities "without compromising safety" and that FDA reviewers apply the same standards to all applications.^[1]

Why it matters for patients

For people weighing an oral GLP-1 option, the timeline for FDA action on orforglipron affects when it might become available and under what level of scrutiny. The dispute described by Reuters is about how much time reviewers get to check an application before a final decision, not about whether the drug works. Still, an FDA source quoted in the report warned that compressed timelines raise the risk that a safety or efficacy issue could be missed or under-examined.^[1] The reporting does not establish whether orforglipron has been approved or whether any additional safety data has been requested after a decision; based on the sourced reporting from December 12, 2025, that remains unclear.^[1]

What happens next

The FDA's National Priority Voucher program, launched in June 2025, has issued 15 vouchers so far, and Commissioner Marty Makary created an internal review council last week to evaluate drugs under the program.^[1] Whether the filing-review timeline is shortened, and whether a decision on orforglipron arrives by March 28, 2026, or the previously set May 20, 2026 target, was not resolved as of the Reuters report.^[1]